Success Metrics

Clinical Success Rate
80.0%

Based on 12 completed trials

Completion Rate
80%(12/15)
Active Trials
1(4%)
Results Posted
42%(5 trials)
Terminated
3(12%)

Phase Distribution

Ph phase_1
4
15%
Ph phase_3
3
12%
Ph phase_4
1
4%
Ph phase_2
18
69%

Phase Distribution

4

Early Stage

18

Mid Stage

4

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
4(15.4%)
Phase 2Efficacy & side effects
18(69.2%)
Phase 3Large-scale testing
3(11.5%)
Phase 4Post-market surveillance
1(3.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

12 of 15 finished

Non-Completion Rate

20.0%

3 ended early

Currently Active

1

trials recruiting

Total Trials

26

all time

Status Distribution
Active(1)
Completed(12)
Terminated(3)
Other(10)

Detailed Status

Completed12
unknown10
Terminated3
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
1
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (15.4%)
Phase 218 (69.2%)
Phase 33 (11.5%)
Phase 41 (3.8%)

Trials by Status

completed1246%
unknown1038%
recruiting14%
terminated312%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT03312400Phase 2

Low-Dose Danazol for the Treatment of Telomere Related Diseases

Recruiting
NCT07183787Phase 2

Letrozole vs Danazol for Endometriosis-Related Pain: Randomized Trial

Completed
NCT04638517Phase 2

The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis

Terminated
NCT00953771Phase 2

Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)

Terminated
NCT06176911Phase 2

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT04173494Phase 3

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Completed
NCT04997811Phase 2

Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes

Unknown
NCT05852847Phase 2

Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT05697471Phase 3

Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis

Unknown
NCT05494307Phase 2

The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT05471050Phase 2

The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT05281068Phase 2

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT05353673Phase 2

The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT04757532Phase 1

Study of Exposure to Substances Prohibited by the World Anti-Doping Agency in Healthy Volunteers.

Completed
NCT04481282Phase 2

The Combination of Terbutaline and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT01001598Phase 1

Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita

Terminated
NCT01441037Phase 1

Danazol for Genetic Bone Marrow and Lung Disorders

Completed
NCT03563664Phase 3

Effect of Danazol on Endometrial αvβ3 Integrin Expression in Patients With Unexplained Recurrent Implantation Failure

Completed
NCT03460808Phase 1

The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown
NCT01732445Phase 2

Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
26